ROYCE BIOMEDICAL INC
NT 10-K, 2000-09-26
PHARMACEUTICAL PREPARATIONS
Previous: BEAR STEARNS ASSET BACKED SECURITIES INC, 424B5, 2000-09-26
Next: ARCH CAPITAL GROUP LTD, S-4/A, 2000-09-26





                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                                    SEC File Number 0-29895
                                                    CUSIP Number 780918 20 7

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                  (Check One):

[X] Form 10-K  [  ] Form 20-F  [  ] Form 11-K  [  ] Form 10-Q  [  ] Form N-SAR

For Period Ended: June 30, 2000
---------------------------------

    Nothing in this Form shall be  construed  to imply that the  Commission  has
verified any information contained herein.
---------------------------------

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the Item(s) to which the notification relates: N/A
---------------------------------

Part I - Registrant Information
---------------------------------

Full Name of Registrant:      Royce Biomedical, Inc.

Former Name if Applicable:  N/A

Address of Principal Executive Office (Street and Number)

      1100-1200 West 73rd Avenue

City, State and Zip Code

      Vancouver, British Columbia Canada  V6P 6G5



<PAGE>


---------------------------------
Part II - Rules 12b-25(b) and (c)
---------------------------------

    If the subject  report  could not be filed  without  unreasonable  effort or
expense  and  the  registrant  seeks  relief  pursuant  to Rule  12b-25(b),  the
following should be completed. (Check box if appropriate)

    (a)  The reasons  described  in  reasonable  detail in Part III of this form
         could not be eliminated without unreasonable effort or expense;

[X] (b)  The subject annual report, semi-annual report, or transition report
         or portion  thereof will be filed on or before the  fifteenth  calendar
         day following the prescribed due date; or the subject  quarterly report
         or transition  report on Form l0-Q or portion  thereof will be filed on
         or before the fifth calendar day following the prescribed due date; and

    (c)  The accountant's  statement or other exhibit required by Rule 12b-25(c)
         has been attached if applicable.

------------------------------------

Part III - Narrative
------------------------------------

    State below in reasonable  detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, or N-SAR,  or the transition  report or portion thereof could not be filed
within the prescribed time period.

    This is the  Company's  first  annual  report on Form  10-KSB.  As a result,
additional time is needed to file the report.

-------------------------------------

Part IV - Other Information
-------------------------------------

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification

       William T. Hart                  (303)                   839-0061
      -----------------            ----------------        ------------------
          (Name)                      (Area Code)          (Telephone Number)



<PAGE>


    (2)  Have all other periodic  reports  required under Section 13 or 15(d) of
         the Securities  Exchange Act of 1934 during the preceding l2 months (or
         for such shorter  period that the  registrant was required to file such
         reports) been filed? If answer
         is no, identify report(s).                       [X] Yes  [  ] No

    (3)  Is it anticipated that any significant  change in results of operations
         from  the  corresponding  period  for  the  last  fiscal  year  will be
         reflected by the earnings statements to be included in the subject
         report or portion thereof?
                                                         [  ] Yes  [X] No

         If  so:  attach  an  explanation  of  the  anticipated   change,   both
         narratively and quantitatively,  and, if appropriate, state the reasons
         why a reasonable estimate of the results cannot be made.

                             Royce Biomedical, Inc.
                     ------------- -----------------------
                  (Name of Registrant as specified in charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


Date:  September 26, 2000       By  /s/ Greg Sharpe
                                    --------------------------------------
                                    Greg Sharpe
                                    Vice President


                                    ATTENTION

Intentional  misstatements  or omissions  of fact  constitute  Federal  Criminal
Violations (See 18 U.S.C. 1001).





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission